Cleared Traditional

K142965 - Virtuoso System for IHC PR (1E2) using iScan HT (FDA 510(k) Clearance)

Jul 2015
Decision
275d
Days
Class 2
Risk

K142965 is an FDA 510(k) clearance for the Virtuoso System for IHC PR (1E2) using iScan HT. This device is classified as a Automated Digital Image Manual Interpretation Microscope (Class II - Special Controls, product code OEO).

Submitted by Ventana Medical Systems, Inc. (Mountain View, US). The FDA issued a Cleared decision on July 16, 2015, 275 days after receiving the submission on October 14, 2014.

This device falls under the Pathology FDA review panel. Regulated under 21 CFR 864.1860. The Ihc Her2 Manual Read Of A Digital Slide Application Is Intended For Use As An Aid To The Pathologist In The Detection And Semi-quantitative Measurement Of Her2/neu (c-erbb-2) In Formalin-fixed, Paraffin-embedded Normal And Neoplastic Tissue Immunohistochemically Stained For Her-2 Receptors, Using Microscopy Images Displayed On A Computer Monitor. Her-2 Results Are Indicated For Use As An Aid In The Management, Prognosis And Prediction Of Therapy Outcomes In Breast Cancer..

Submission Details

510(k) Number K142965 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 14, 2014
Decision Date July 16, 2015
Days to Decision 275 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary Summary PDF

Device Classification

Product Code OEO — Automated Digital Image Manual Interpretation Microscope
Device Class Class II - Special Controls
CFR Regulation 21 CFR 864.1860
Definition The Ihc Her2 Manual Read Of A Digital Slide Application Is Intended For Use As An Aid To The Pathologist In The Detection And Semi-quantitative Measurement Of Her2/neu (c-erbb-2) In Formalin-fixed, Paraffin-embedded Normal And Neoplastic Tissue Immunohistochemically Stained For Her-2 Receptors, Using Microscopy Images Displayed On A Computer Monitor. Her-2 Results Are Indicated For Use As An Aid In The Management, Prognosis And Prediction Of Therapy Outcomes In Breast Cancer.